Administer prepared ADAKVEO® infusion solution immediately1
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. Store the prepared solution either:1
- At room temperature up to 25°C for no more than 4.5 hours from the start of the preparation to the completion of infusion
- Under refrigeration at 2°C to 8°C for no more than 24 hours from the start of preparation to the completion of infusion. This includes the storage of the diluted solution and the time to warm up to room temperature
ADAKVEO® is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting suspected adverse reactions after authorisation of ADAKVEO® is important to understand the safety profile of the treatment for SCD patients.
Indication: ADAKVEO® (crizanlizumab) is indicated for the prevention of recurrent VOCs in patients with SCD who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1
ADAKVEO® has a conditional marketing authorisation and further evidence is awaited.
Abbreviations: HC, hydroxycarbamide; HU, hydroxyurea; SCD, sickle cell disease; VOC, vaso-occlusive crisis.
- ADAKVEO® Summary of Product Characteristics.